The Brazilian medical laboratory group Fleury said this Monday (17) that its board of directors has approved a new capital increase of up to R$1.22 billion with the aim of maintaining the company’s growth strategy and strengthening its position as a Cashier.
Fleury will issue between 34,896,418 and 70,567,969 shares at a price of R$ 17.27 each through private subscription, according to a relevant fact to the market.
The price represents a discount of 6.5% compared to the closing level of the paper on Friday (14), at R$ 18.47.
The total value of the capital increase could range from R$602.6 million to R$1.22 billion, the company said.
The group has been expanding through acquisitions recently, including the purchase of Instituto Hermes Pardini, announced in June and which still depends on regulatory approval.
At the time of the announcement, Fleury stated that, until the completion of the transaction with Pardini, it could carry out a capital increase of up to 70.6 million shares, by private subscription or public offering.
In recent weeks, Fleury also announced the acquisitions of the ophthalmology group Retina Clinic and the medical laboratory company Méthodos Laboratório.
Source: CNN Brasil

Joe Jameson, a technology journalist with over 2 years of experience, writes for top online news websites. Specializing in the field of technology, Joe provides insights into the latest advancements in the industry. Currently, he contributes to covering the world stock market.